Product Information
Acetic acid, benzyl(1-cyclopropylethyl)amine (ABE) is a new drug candidate for the treatment of type II diabetes. ABE has been shown to inhibit the growth of Candida glabrata at a concentration of 0.5 mM and to be effective against c. albicans at a concentration of 1 mM. ABE also exhibits an optimum concentration in the range of 0.25-0.5 M, which can be achieved by diluting it with 50% ethanol or water for injection and then filtering the solution before administration, as well as through pretreatment with cerevisiae or Saccharomyces cerevisiae (a yeast). ABE has been shown to have hypoglycemic effects in both yeast and mouse models of type II diabetes, although it has not yet been tested on humans.
Chemical properties
Technical inquiry about: Acetic acid, benzyl(1-cyclopropylethyl)amine
Please use instead the cart to request a quotation or an order